Wei ZHANG

Prof. Dr. Wei ZHANG


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2022 in Brain Research Bulletin
Verified
Journal Article
Open access
XLXinyao Liu
Xinyao Liu
YDYue Du
Yue Du
JLJian Liu
Jian Liu
LCLinggang Cheng
Linggang Cheng
WHWen He
Wen He
WZWei ZHANG
Wei ZHANG
Ischemic stroke is the major cause of disability and death worldwide, but post-stroke neuronal death and related mechanisms remain unclear. Ferroptosis, a newly identified type of regulated cell death, has been shown to be associated with neurological disorders, yet the exact relationship between ferroptosis and ischemic stroke has not been elucidated. The purpose of this study is to investigate the effects of ferroptosis-specific inhibitor ferrostatin-1 (Fer-1) on neuronal injury after cerebral ischemia/reperfusion (I/R) and the underlying mechanism. In this study, we demonstrated that ferroptosis does occur in the stroke model. We found that Fer-1 reduced the levels of iron and malondialdehyde, and increased the content of glutathione and the expression of solute carrier family 7 member 11 and glutathione peroxidase 4 in cerebral I/R models. Additionally, Fer-1 significantly reduced the infarct volume and improved neurobehavioral outcomes. Moreover, we found that Fer-1 increased the levels of phosphorylated AKT and GSK3β following cerebral I/R. To further investigate the functional role of the AKT in the neuroprotective effects of Fer-1, MCAO models and oxygen-glucose deprivation-induced HT22 cells were pretreated with the AKT inhibitor MK-2206 before treatment with Fer-1 and the protective effects of Fer-1 were reversed. In conclusion, Fer-1 has protective effects on cerebral I/R injury by activating the AKT/GSK3β pathway, indicating that ferroptosis may become a novel target in the treatment of ischemic stroke.

1 May 2024 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
CHChao Hou
Chao Hou
FYFang Yang
Fang Yang
SLShuo Li
Shuo Li
HMHui-Yu Ma
Hui-Yu Ma
FLFang-Xian Li
Fang-Xian Li
WHWen He
Wen He
Background: One in four individuals with Parkinson’s disease (PD) experience cognitive impairment (CI). However, few practical models integrating clinical and neuroimaging biomarkers have been developed to address CI in PD. This study aimed to evaluate the correlation between circulating neuron-specific enolase (NSE) levels, substantia nigra hyperechogenicity (SNH), and cognitive function in PD and to develop a nomogram based on clinical and neuroimaging biomarkers for predicting CI in patients with PD. Methods: A total of 385 patients with PD who underwent transcranial sonography (TCS) from January 2021 to December 2022 at Beijing Tiantan Hospital, Capital Medical University, were recruited as the training cohort. For validation, 165 patients with PD treated from January 2023 to December 2023 were enrolled. Data for SNH, plasma NSE, and other clinical measures were collected, and cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Logistic regression analysis was employed to select potential risk factors and establish a nomogram. The receiver operating characteristic curve and calibration curve were generated to evaluate the performance of the nomogram. Results: Patients with PD exhibiting CI displayed advanced age, elevated Unified PD Rating Scale-III (UPDRS-III) score, an increased percentage of SNH, higher levels of plasma NSE and homocysteine (Hcy), a larger SNH area, and lower education levels compared to PD patients without CI. Gender [odds ratio (OR) =0.561, 95% confidence interval (CI): 0.330–0.954, P=0.03], age (OR =1.039; 95% CI: 1.011–1.066; P=0.005), education level (OR =0.892; 95% CI: 0.842–0.954; P<0.001), UPDRS-III scores (OR =1.026; 95% CI: 1.009–1.043; P=0.003), plasma NSE concentration (OR =1.562; 95% CI: 1.374–1.776; P<0.001), and SNH (OR =0.545; 95% CI: 0.330–0.902; P=0.02) were independent predictors of CI in patients with PD. A nomogram developed using these six factors yielded a moderate discrimination performance with an area under the curve (AUC) of 0.823 (95% CI 0.781–0.864; P<0.001). The calibration curve demonstrated acceptable agreement between predicted outcomes and actual values. Validation further confirmed the reliability of the nomogram, with an AUC of 0.864 (95% CI: 0.805–0.922; P<0.001). Conclusions: The level of NSE in plasma and the SNH assessed by TCS are associated with CI in patients with PD. The proposed nomogram has the potential to facilitate the detection of cognitive decline in individuals with PD.

9 January 2026 in Clinical Parkinsonism & Related Disorders
Verified
Journal Article
Open access
SWSen Wang
Sen Wang
YCYujie Che
Yujie Che
YLYiqun Lin
Yiqun Lin
YZYukang Zhang
Yukang Zhang
WHWen He
Wen He
WZWei ZHANG
Wei ZHANG
Parkinson’s disease (PD), a common neurodegenerative disorder, severely affects patients’ quality of life. This study aims to update the assessment of PD’s prevalence, incidence, mortality, and disability–adjusted life years (DALYs) from 1990 to 2021. Analyses were conducted at Socio-demographic Index (SDI), global, regional, and national levels, stratified by gender and age. PD data from the Global Burden of Disease (GBD) 2021 database was extracted. Trends in age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR) of PD were assessed, and estimated annual percentage change (EAPC) was calculated during the study period. Analyses were done by gender, age, GBD region, and SDI quintiles, using R statistical software for analyses and mapping. In 2021, the global burden of PD remained substantial. The number of prevalent PD cases grew from 3,148,394.56 in 1990 to 11,767,271.97 in 2021 (a 2.74-fold increase). Incident cases rose from 417,134.69 to 1,335,142.12 (a 2.20-fold increase). Males exhibited higher prevalence, incidence, and mortality rates than females across almost all age groups. High-SDI regions had higher ASPR, ASIR, and ASDR values than low-SDI regions. Countries and regions in Asia, particularly China and Japan, exhibited among the highest ASPR and ASIR globally. Projections indicate global ASPR and ASIR will continue to rise substantially over the next three decades (to 2050), with males exhibiting a faster rate of increase than females, while the ASMR is predicted to remain essentially stable. This study systematically delineates the epidemiological landscape, temporal trends, and burden profiles of Parkinson’s disease across global, regional, gender-stratified, and age-specific populations, providing an evidence-based framework to guide precision prevention strategies and optimize healthcare resource prioritization.

20 December 2024 in Nanoscale
Verified
Journal Article
Closed access
PDF file
LYLizhi Yang
Lizhi Yang
SLShuo Li
Shuo Li
CHChao Hou
Chao Hou
Zihua WangZihua Wang
Zihua Wang
WHWen He
Wen He
WZWei ZHANG
Wei ZHANG
MRNA-based therapeutics have entered the mainstream with seemingly limitless possibilities to treat neurodegenerative diseases and brain tumors.

1 January 2024 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
CHChao Hou
Chao Hou
SLShuo Li
Shuo Li
SZShuai Zheng
Shuai Zheng
LLLu-Ping Liu
Lu-Ping Liu
FNFang Nie
Fang Nie
WHWen He
Wen He
Background: Although imaging techniques provide information about the morphology and stability of carotid plaque, they are operator dependent and may miss certain subtleties. A variety of radiomics models for carotid plaque have recently been proposed for identifying vulnerable plaques and predicting cardiovascular and cerebrovascular diseases. The purpose of this review was to assess the risk of bias, reporting, and methodological quality of radiomics models for carotid atherosclerosis plaques. Methods: A systematic search was carried out to identify available literature published in PubMed, Web of Science, and the Cochrane Library up to March 2023. Studies that developed and/or validated machine learning models based on radiomics data to identify and/or predict unfavorable cerebral and cardiovascular events in carotid plaque were included. The basic information of each piece of included literature was identified, and the reporting quality, risk of bias, and radiomics methodology quality were assessed according the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) checklist, the Prediction Model Risk of Bias Assessment Tool (PROBAST), and the radiomics quality score (RQS), respectively. Results: A total of 2,738 patients from 19 studies were included. The mean overall TRIPOD adherence rate was 66.1% (standard deviation 12.8%), with a range of 45–87%. All studies had a high overall risk of bias, with the analysis domain being the most common source of bias. The mean RQS was 9.89 (standard deviation 5.70), accounting for 27.4% of the possible maximum value of 36. The mean area under the curve for diagnostic or predictive properties of these included radiomics models was 0.876±0.09, with a range of 0.741–0.989. Conclusions: Radiomics models may have value in the assessment of carotid plaque, the overall scientific validity and reporting quality of current carotid plaque radiomics reports are still lacking, and many barriers must be overcome before these models can be applied in clinical practice.

18 March 2024 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
CHChao Hou
Chao Hou
SLShuo Li
Shuo Li
LZLei Zhang
Lei Zhang
WZWei ZHANG
Wei ZHANG
WHWen He
Wen He
Objective: This study aimed to examine the clinical and multimodal ultrasonic characteristics differences between carotid web (CW) and CW with plaque as well as the potential risk factors for stroke caused by CW. Methods: We retrospectively enrolled patients diagnosed with CW by CTA or high-resolution MRI (HRMRI) and simultaneously underwent contrast enhanced ultrasound (CEUS) and superb microvascular imaging examinations from January 2015 to October 2022. The CW angle was measured using computer-aided software. The variations between CW and CW with plaque were evaluated, and univariable and multivariable logistic regressions were utilized to identify possible risk predictors for stroke caused by CW. Results: Two hundred ninety-nine patients with an average age of 60.85 (± 8.77) years were included. Sex, age, history of smoking, alcohol, hypertension, diabetes mellitus, homocysteine level, and treatment, as well as web length and thickness, luminal stenosis, location wall, number, CW angle, and CEUS enhancement, were quite different among CW and CW with plaque patients (p < 0.05). The logistic regression analysis showed that web length was an independent predictor of luminal stenosis in CW patients. For patients with CW and plaque, plaque and web thickness, as well as plaque enhancement, were associated with stenosis. Furthermore, luminal stenosis and plaque length were risk factors for symptoms. Conclusion: The multimodal ultrasonic and clinical manifestations of CW and CW with plaque are quite different. Web length is an independent risk factor for carotid artery stenosis in CW patients, whereas luminal stenosis and plaque length were risk factors for symptoms in CW with plaque patients. Critical relevance statement: Exploring the similarities and differences between the carotid web and the carotid web with plaque, based on the stereo-geometric spatial position relationship and hemodynamic changes, may provide further insights into the underlying mechanisms of stroke occurrence caused by the carotid web. Key points: 1. Multimodal ultrasonic and clinical manifestations of carotid web and carotid web with plaque are substantially different. 2. A thin triangular endoluminal defect is identified as a typical feature of the web on superb microvascular imaging, and two kinds of typical ultrasonic features of CW with plaque are also identified. 3. Web length is an independent risk factor for carotid stenosis in carotid web patients, whereas luminal stenosis and plaque length are risk factors for symptoms in patients with CW and plaque. Graphical